miRNA and cholesterol homeostasis

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1861, Issue 12, 2016, Pages 2041-2046

  Jeon, Tae Il ^a   Osborne, Timothy F ^b  

^a Chonnam National University   (South Korea)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Cholesterol metabolism; Metabolic disease; MicroRNA; Transcription factor

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR; MICRORNA; MICRORNA 122; MICRORNA 34A; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR;

BIOGENESIS; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; FATTY ACID OXIDATION; GENE EXPRESSION; GENE REGULATORY NETWORK; HOMEOSTASIS; HUMAN; LIPOGENESIS; METABOLIC DISORDER; METABOLIC REGULATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; REVIEW; RNA TRANSCRIPTION; ANIMAL; ENERGY METABOLISM; GENETICS; LIPID METABOLISM;

ANIMALS; CHOLESTEROL; ENERGY METABOLISM; GENE REGULATORY NETWORKS; HOMEOSTASIS; HUMANS; LIPID METABOLISM; METABOLIC DISEASES; MICRORNAS; TRANSCRIPTION FACTORS;

EID: 84956621960     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2016.01.005     Document Type: Review

References (62)

1. [1] Maxfield, F.R., Tabas, I., Role of cholesterol and lipid organization in disease. Nature 438 (2005), 612–621.
2. [2] Luu, W., Sharpe, L.J., Gelissen, I.C., Brown, A.J., The role of signalling in cellular cholesterol homeostasis. IUBMB Life 65 (2013), 675–684.
3. [3] Rottiers, V., Naar, A.M., MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 13 (2012), 239–250.
4. [4] Osborne, T.F., Espenshade, P.J., Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it's been. Genes Dev. 23 (2009), 2578–2591.
5. [5] Osborne, T.F., Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J. Biol. Chem. 275 (2000), 32379–32382.
6. [6] Jeon, T.I., Osborne, T.F., SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol. Metab. 23 (2012), 65–72.
7. [7] Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
8. [8] Huntzinger, E., Izaurralde, E., Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 12 (2011), 99–110.
9. [9] Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
10. [10] Borchert, G.M., Lanier, W., Davidson, B.L., RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol. 13 (2006), 1097–1101.
11. [11] Kim, V.N., Han, J., Siomi, M.C., Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10 (2009), 126–139.
12. [12] Saini, H.K., Griffiths-Jones, S., Enright, A.J., Genomic analysis of human microRNA transcripts. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 17719–17724.
13. [13] Monteys, A.M., Spengler, R.M., Wan, J., Tecedor, L., Lennox, K.A., Xing, Y., Davidson, B.L., Structure and activity of putative intronic miRNA promoters. RNA 16 (2010), 495–505.
14. [14] Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15 (2014), 509–524.
15. [15] Lee, Y., Kim, M., Han, J., Yeom, K.H., Lee, S., Baek, S.H., Kim, V.N., MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23 (2004), 4051–4060.
16. [16] Ozsolak, F., Poling, L.L., Wang, Z., Liu, H., Liu, X.S., Roeder, R.G., Zhang, X., Song, J.S., Fisher, D.E., Chromatin structure analyses identify miRNA promoters. Genes Dev. 22 (2008), 3172–3183.
17. [17] Lee, J., Li, Z., Brower-Sinning, R., John, B., Regulatory circuit of human microRNA biogenesis. PLoS Comput. Biol., 3, 2007, e67.
18. [18] Marson, A., Levine, S.S., Cole, M.F., Frampton, G.M., Brambrink, T., Johnstone, S., Guenther, M.G., Johnston, W.K., Wernig, M., Newman, J., Calabrese, J.M., Dennis, L.M., Volkert, T.L., Gupta, S., Love, J., Hannett, N., Sharp, P.A., Bartel, D.P., Jaenisch, R., Young, R.A., Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 134 (2008), 521–533.
19. [19] Radhakrishnan, A., Goldstein, J.L., McDonald, J.G., Brown, M.S., Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 8 (2008), 512–521.
20. [20] Jeon, T.I., Esquejo, R.M., Roqueta-Rivera, M., Phelan, P.E., Moon, Y.A., Govindarajan, S.S., Esau, C.C., Osborne, T.F., An SREBP-responsive microRNA operon contributes to a regulatory loop for intracellular lipid homeostasis. Cell Metab. 18 (2013), 51–61.
21. [21] Miao, J., Ling, A.V., Manthena, P.V., Gearing, M.E., Graham, M.J., Crooke, R.M., Croce, K.J., Esquejo, R.M., Clish, C.B., G. Morbid Obesity Study, Vicent, D., Biddinger, S.B., Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat. Commun., 6, 2015, 6498.
22. [22] Ng, R., Wu, H., Xiao, H., Chen, X., Willenbring, H., Steer, C.J., Song, G., Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology 60 (2014), 554–564.
23. [23] Cheung, O., Puri, P., Eicken, C., Contos, M.J., Mirshahi, F., Maher, J.W., Kellum, J.M., Min, H., Luketic, V.A., Sanyal, A.J., Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48 (2008), 1810–1820.
24. [24] Smith, E.M., Zhang, Y., Baye, T.M., Gawrieh, S., Cole, R., Blangero, J., Carless, M.A., Curran, J.E., Dyer, T.D., Abraham, L.J., Moses, E.K., Kissebah, A.H., Martin, L.J., Olivier, M., INSIG1 influences obesity-related hypertriglyceridemia in humans. J. Lipid Res. 51 (2010), 701–708.
25. [25] Yang, M., Liu, W., Pellicane, C., Sahyoun, C., Joseph, B.K., Gallo-Ebert, C., Donigan, M., Pandya, D., Giordano, C., Bata, A., Nickels, J.T. Jr., Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J. Lipid Res. 55 (2014), 226–238.
26. [26] Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., Stoffel, M., Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438 (2005), 685–689.
27. [27] Esau, C., Davis, S., Murray, S.F., Yu, X.X., Pandey, S.K., Pear, M., Watts, L., Booten, S.L., Graham, M., McKay, R., Subramaniam, A., Propp, S., Lollo, B.A., Freier, S., Bennett, C.F., Bhanot, S., Monia, B.P., miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3 (2006), 87–98.
28. [28] Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjarn, M., Hansen, H.F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E.M., Kauppinen, S., LNA-mediated microRNA silencing in non-human primates. Nature, 452, 2008, 896-U810.
29. [29] Min, H.K., Kapoor, A., Fuchs, M., Mirshahi, F., Zhou, H., Maher, J., Kellum, J., Warnick, R., Contos, M.J., Sanyal, A.J., Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 15 (2012), 665–674.
30. [30] Yamakuchi, M., Ferlito, M., Lowenstein, C.J., miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 13421–13426.
31. [31] Walker, A.K., Yang, F., Jiang, K., Ji, J.Y., Watts, J.L., Purushotham, A., Boss, O., Hirsch, M.L., Ribich, S., Smith, J.J., Israelian, K., Westphal, C.H., Rodgers, J.T., Shioda, T., Elson, S.L., Mulligan, P., Najafi-Shoushtari, H., Black, J.C., Thakur, J.K., Kadyk, L.C., Whetstine, J.R., Mostoslavsky, R., Puigserver, P., Li, X., Dyson, N.J., Hart, A.C., Naar, A.M., Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 24 (2010), 1403–1417.
32. [32] Lee, J., Padhye, A., Sharma, A., Song, G., Miao, J., Mo, Y.Y., Wang, L., Kemper, J.K., A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J. Biol. Chem. 285 (2010), 12604–12611.
33. [33] Yahagi, N., Shimano, H., Matsuzaka, T., Sekiya, M., Najima, Y., Okazaki, S., Okazaki, H., Tamura, Y., Iizuka, Y., Inoue, N., Nakagawa, Y., Takeuchi, Y., Ohashi, K., Harada, K., Gotoda, T., Nagai, R., Kadowaki, T., Ishibashi, S., Osuga, J., Yamada, N., p53 involvement in the pathogenesis of fatty liver disease. J. Biol. Chem. 279 (2004), 20571–20575.
34. [34] Chaudhary, N., Pfluger, P.T., Metabolic benefits from Sirt1 and Sirt1 activators. Curr. Opin. Clin. Nutr. Metab. Care 12 (2009), 431–437.
35. [35] Castro, R.E., Ferreira, D.M., Afonso, M.B., Borralho, P.M., Machado, M.V., Cortez-Pinto, H., Rodrigues, C.M., miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J. Hepatol. 58 (2013), 119–125.
36. [36] Vickers, K.C., Landstreet, S.R., Levin, M.G., Shoucri, B.M., Toth, C.L., Taylor, R.C., Palmisano, B.T., Tabet, F., Cui, H.L., Rye, K.A., Sethupathy, P., Remaley, A.T., MicroRNA-223 coordinates cholesterol homeostasis. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 14518–14523.
37. [37] Tall, A.R., Yvan-Charvet, L., Terasaka, N., Pagler, T., Wang, N., HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 7 (2008), 365–375.
38. [38] Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.C., Deleuze, J.F., Brewer, H.B., Duverger, N., Denefle, P., Assmann, G., Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22 (1999), 352–355.
39. [39] Timmins, J.M., Lee, J.Y., Boudyguina, E., Kluckman, K.D., Brunham, L.R., Mulya, A., Gebre, A.K., Coutinho, J.M., Colvin, P.L., Smith, T.L., Hayden, M.R., Maeda, N., Parks, J.S., Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115 (2005), 1333–1342.
40. [40] Najafi-Shoushtari, S.H., Kristo, F., Li, Y., Shioda, T., Cohen, D.E., Gerszten, R.E., Naar, A.M., MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328 (2010), 1566–1569.
41. [41] Rayner, K.J., Suarez, Y., Davalos, A., Parathath, S., Fitzgerald, M.L., Tamehiro, N., Fisher, E.A., Moore, K.J., Fernandez-Hernando, C., MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328 (2010), 1570–1573.
42. [42] Horie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., Hasegawa, K., Yokode, M., Kimura, T., Kita, T., MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 17321–17326.
43. [43] Marquart, T.J., Allen, R.M., Ory, D.S., Baldan, A., miR-33 links SREBP-2 induction to repression of sterol transporters. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 12228–12232.
44. [44] Gerin, I., Clerbaux, L.A., Haumont, O., Lanthier, N., Das, A.K., Burant, C.F., Leclercq, I.A., MacDougald, O.A., Bommer, G.T., Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J. Biol. Chem. 285 (2010), 33652–33661.
45. [45] Rayner, K.J., Sheedy, F.J., Esau, C.C., Hussain, F.N., Temel, R.E., Parathath, S., van Gils, J.M., Rayner, A.J., Chang, A.N., Suarez, Y., Fernandez-Hernando, C., Fisher, E.A., Moore, K.J., Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121 (2011), 2921–2931.
46. [46] Rayner, K.J., Esau, C.C., Hussain, F.N., McDaniel, A.L., Marshall, S.M., van Gils, J.M., Ray, T.D., Sheedy, F.J., Goedeke, L., Liu, X., Khatsenko, O.G., Kaimal, V., Lees, C.J., Fernandez-Hernando, C., Fisher, E.A., Temel, R.E., Moore, K.J., Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478 (2011), 404–407.
47. [47] Rottiers, V., Obad, S., Petri, A., McGarrah, R., Lindholm, M.W., Black, J.C., Sinha, S., Goody, R.J., Lawrence, M.S., deLemos, A.S., Hansen, H.F., Whittaker, S., Henry, S., Brookes, R., Najafi-Shoushtari, S.H., Chung, R.T., Whetstine, J.R., Gerszten, R.E., Kauppinen, S., Naar, A.M., Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci. Transl. Med., 5, 2013 (212ra162).
48. [48] Ramirez, C.M., Davalos, A., Goedeke, L., Salerno, A.G., Warrier, N., Cirera-Salinas, D., Suarez, Y., Fernandez-Hernando, C., MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 2707–2714.
49. [49] Hirsch-Reinshagen, V., Wellington, C.L., Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr. Opin. Lipidol. 18 (2007), 325–332.
50. [50] Donkin, J.J., Stukas, S., Hirsch-Reinshagen, V., Namjoshi, D., Wilkinson, A., May, S., Chan, J., Fan, J., Collins, J., Wellington, C.L., ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J. Biol. Chem. 285 (2010), 34144–34154.
51. [51] Vitali, C., Wellington, C.L., Calabresi, L., HDL and cholesterol handling in the brain. Cardiovasc. Res. 103 (2014), 405–413.
52. [52] Kim, J., Yoon, H., Ramirez, C.M., Lee, S.M., Hoe, H.S., Fernandez-Hernando, C., Kim, J., MiR-106b impairs cholesterol efflux and increases abeta levels by repressing ABCA1 expression. Exp. Neurol. 235 (2012), 476–483.
53. [53] Calkin, A.C., Tontonoz, P., Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 13 (2012), 213–224.
54. [54] Sun, D., Zhang, J., Xie, J., Wei, W., Chen, M., Zhao, X., MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. FEBS Lett. 586 (2012), 1472–1479.
55. [55] Ramirez, C.M., Rotllan, N., Vlassov, A.V., Davalos, A., Li, M., Goedeke, L., Aranda, J.F., Cirera-Salinas, D., Araldi, E., Salerno, A., Wanschel, A., Zavadil, J., Castrillo, A., Kim, J., Suarez, Y., Fernandez-Hernando, C., Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ. Res. 112 (2013), 1592–1601.
56. [56] Ou, Z., Wada, T., Gramignoli, R., Li, S., Strom, S.C., Huang, M., Xie, W., MicroRNA hsa-miR-613 targets the human LXRalpha gene and mediates a feedback loop of LXRalpha autoregulation. Mol. Endocrinol. 25 (2011), 584–596.
57. [57] de Aguiar Vallim, T.Q., Tarling, E.J., Kim, T., Civelek, M., Baldan, A., Esau, C., Edwards, P.A., MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ. Res. 112 (2013), 1602–1612.
58. [58] Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H., Krieger, M., Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 (1996), 518–520.
59. [59] Rader, D.J., Alexander, E.T., Weibel, G.L., Billheimer, J., Rothblat, G.H., The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50:Suppl (2009), S189–S194.
60. [60] Zhang, Y., Da Silva, J.R., Reilly, M., Billheimer, J.T., Rothblat, G.H., Rader, D.J., Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 115 (2005), 2870–2874.
61. [61] Wang, L., Jia, X.J., Jiang, H.J., Du, Y., Yang, F., Si, S.Y., Hong, B., MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol. Cell. Biol. 33 (2013), 1956–1964.
62. [62] Hu, Z., Shen, W.J., Kraemer, F.B., Azhar, S., MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells. Mol. Cell. Biol. 32 (2012), 5035–5045.